Download PDF
Semin Vasc Med 2005; 5(1): 25-33
DOI: 10.1055/s-2005-871739
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA. Tel: +1(212) 584-4662.

Obesity and Cardiovascular Disease: Pathogenic Mechanisms and Potential Benefits of Weight Reduction

James D. Douketis1 , Arya M. Sharma1
  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
21 June 2005 (online)

    Permissions and Reprints

ABSTRACT

The prevalence of obesity in industrialized countries has reached epidemic proportions, with about one in three people being obese and another one in three people being overweight and at risk of developing obesity. In recent years, obesity has gained the traditional tetrad of cardiovascular risk factors of smoking: hypertension, dyslipidemia, and dysglycemia. Attention has also focused on the importance of abdominal (or central) obesity as a determinant of cardiovascular risk, independent of the body mass index. In addition to effects on coronary artery disease, obesity has an effect on cardiovascular disease, including stroke, ventricular function, peripheral arterial disease, and venous thromboembolism. The objectives of this review are to summarize the effects of obesity on cardiovascular disease, and the possible mechanisms for these associations, and to investigate the effects of weight-loss interventions on the burden of cardiovascular disease. Large ongoing clinical outcome trials, such as the SOS study, the Look-AHEAD trial, or the SCOUT study, should provide important information on the effects of surgical and nonsurgical obesity treatment on cardiovascular morbidity and mortality.

KEYWORDS

Obesity - pathogenesis - weight loss - cardiovascular disease

REFERENCES

  • 1 Assmann G, Carmena R, Cullen P et al.. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease.  Circulation. 1999;  100 1930-1938
    PubMedGoogle Scholar
  • 2 World Health Organization Consultation on Obesity .Obesity: preventing and managing the global epidemic. Geneva; World Health Organization 2000
    Google Scholar
  • 3 Rabkin S W, Chen Y, Leiter L, Liu L, Reeder B A. Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group.  CMAJ. 1997;  157 Suppl 1 S26-S31
    PubMedGoogle Scholar
  • 4 Eckel R H, Krauss R M. for the AHA Nutrition Committee, American Heart Association: call to action: obesity as a major risk factor for coronary heart disease.  Circulation. 1998;  97 2099-2100
    PubMedGoogle Scholar
  • 5 Han T S, van Leer E M, Seidell J C, Lean M E. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample.  BMJ. 1995;  311 1401-1405
    CrossrefPubMedGoogle Scholar
  • 6 Donohue R P, Abbott R D, Bloom E, Reed D M, Yano K. Central obesity and coronary heart disease in men.  Lancet. 1987;  1 821-824
    PubMedGoogle Scholar
  • 7 Lean M E, Han T S, Seidell J C. Impairment of health and quality of life in people with large waist circumference.  Lancet. 1998;  351 853-856
    CrossrefPubMedGoogle Scholar
  • 8 Lemieux I, Pascot A, Couillard C et al.. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?.  Circulation. 2000;  102(2) 179-184
    PubMedGoogle Scholar
  • 9 Despres J P. Health consequences of visceral obesity.  Ann Med. 2001;  33 534-541
    PubMedGoogle Scholar
  • 10 Mokdad A H, Serdula M K, Dietz W H, Bowman B A, Marks J S, Koplan J P. The spread of the obesity epidemic in the United States, 1991-1998.  JAMA. 1999;  282 1519-1522
    CrossrefPubMedGoogle Scholar
  • 11 Katzmarzyk P T. The Canadian obesity epidemic, 1985-1998.  CMAJ. 2002;  166 1039-1040
    PubMedGoogle Scholar
  • 12 Seidell J C. The epidemiology of obesity. in Björntorp P International Textbook of Obesity Chichester; Wiley 2001: 23-29
    Google Scholar
  • 13 Martorell R, Kettel-Khan L, Hughes M L, Grummer-Strawn L M. Obesity in women from developing countries.  Eur J Clin Nutr. 2000;  54 247-252
    CrossrefPubMedGoogle Scholar
  • 14 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999-2000.  JAMA. 2002;  288 1723-1727
    CrossrefPubMedGoogle Scholar
  • 15 King H, Aubert R E, Herman W H. Global burden of diabetes, 1995-2025.  Diabetes Care. 1998;  21 1414-1431
    CrossrefPubMedGoogle Scholar
  • 16 Keys A, Menotti A, Aravanis C et al.. The seven countries study: 2289 deaths in 15 years.  Prev Med. 1984;  13 141-154
    CrossrefPubMedGoogle Scholar
  • 17 Rimm E B, Stampfer M J, Giovannucci E et al.. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.  Am J Epidemiol. 1995;  141(12) 1117-1127
    PubMedGoogle Scholar
  • 18 Manson J E, Colditz G A, Stampfer M J et al.. A prospective study of obesity and risk of coronary heart disease in women.  N Engl J Med. 1990;  322 882-889
    CrossrefPubMedGoogle Scholar
  • 19 Rosengren A, Wedel H, Wilhelmsen L et al.. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study.  Eur Heart J. 1999;  20(4) 269-277
    CrossrefPubMedGoogle Scholar
  • 20 Manson J E, Willet W C, Stampfer M J et al.. Body weight and mortality among women.  N Engl J Med. 1995;  333 677-685
    CrossrefPubMedGoogle Scholar
  • 21 Stevens J, Cai J, Pamuk E R, Williamson D F, Thun M J, Wood J L. The effect of age on the association between body mass index and mortality.  N Engl J Med. 1998;  338 1-7
    CrossrefPubMedGoogle Scholar
  • 22 Engeli S, Sharma A M. Role of adipose tissue for cardiovascular-renal regulation in health and disease.  Horm Metab Res. 2000;  32 485-499
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Haynes W G. Interaction between leptin and sympathetic nervous system in hypertension.  Curr Hypertens Rep. 2000;  2 311-318
    PubMedGoogle Scholar
  • 24 Parhami P, Tintut Y, Ballard A, Fogelman A M, Demer L L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin.  Circ Res. 2001;  88 954-960
    PubMedGoogle Scholar
  • 25 Narklewicz K, Kato M, Phillips B G et al.. Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects.  J Hypertens. 2001;  19 1089-1094
    CrossrefPubMedGoogle Scholar
  • 26 Engeli S, Negrel R, Sharma A M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system.  Hypertension. 2000;  35 1270-1277
    CrossrefPubMedGoogle Scholar
  • 27 Ouchi N, Kihara S, Arita Y et al.. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.  Circulation. 1999;  100 2473-2476
    CrossrefPubMedGoogle Scholar
  • 28 Lohn M, Dubrovska G, Lauterbach B, Luft F C, Gollasch M, Sharma A M. Periadvential fat releases a vascular relaxing factor.  FASEB J. 2002;  16 1057-1063
    CrossrefPubMedGoogle Scholar
  • 29 Heilbronn L K, Noakes M, Clifton P M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women.  Arterioscler Thromb Vasc Biol. 2001;  21 968-970
    CrossrefPubMedGoogle Scholar
  • 30 Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women.  Int J Obes Relat Metab Disord. 2001;  25 212-218
    CrossrefPubMedGoogle Scholar
  • 31 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med. 1997;  336 973-979
    CrossrefPubMedGoogle Scholar
  • 32 Lundgren C H, Brown S L, Nordt T K, Sobel B E, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential link between obesity and cardiovascular disease.  Circulation. 1996;  93 106-110
    PubMedGoogle Scholar
  • 33 Abott R D, Behrens G R, Sharp D S et al.. Body mass index and thromboembolic stroke in nonsmoking men in older middle age: the Honolulu Heart Program.  Stroke. 1994;  25 2370-2376
    PubMedGoogle Scholar
  • 34 Hubert H B, Feinleib M, McNamara P M, Castelli W P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.  Circulation. 1983;  67 968-977
    CrossrefPubMedGoogle Scholar
  • 35 Rexrode K M, Hennekens C H, Willett W C et al.. A prospective study of body mass index, weight change, and risk of stroke in women.  JAMA. 1997;  227 1539-1545
    PubMedGoogle Scholar
  • 36 Suk S-H, Sacco R L, Boden-Albala B et al.. Abdominal obesity and risk of ischemic stroke. The Northern Manhattan Stroke Study.  Stroke. 2003;  34 1586-1592
    CrossrefPubMedGoogle Scholar
  • 37 Sacco R L, Boden-Albala B, Abel G et al.. Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study.  Stroke. 2001;  32 1725-1731
    PubMedGoogle Scholar
  • 38 Arcaro G, Zamboni M, Rossi L et al.. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity.  Int J Obes Relat Metab Disord. 1999;  23 936-942
    CrossrefPubMedGoogle Scholar
  • 39 Solorte S B, Fiorvanti M, Pezza N et al.. Hyperviscosity and microproteinuria in central obesity: relevance to cardiovascular risk.  Int J Obes Relat Metab Disord. 1997;  21 417-423
    CrossrefPubMedGoogle Scholar
  • 40 Davi G, Guagnano M T, Ciabattoni G et al.. Platelet activation in obese women: role of inflammation and oxidant stress.  JAMA. 2002;  288 2008-2014
    CrossrefPubMedGoogle Scholar
  • 41 Alpert M A, Terry B E, Mulekar M et al.. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss.  Am J Cardiol. 1997;  80 736-740
    CrossrefPubMedGoogle Scholar
  • 42 Must A, Spadano J, Coakley E H, Field A E, Colditz G, Dietz W H. The disease burden associated with overweight and obesity.  JAMA. 1999;  282 1523-1529
    CrossrefPubMedGoogle Scholar
  • 43 Kuch B, Muscholl M, Luchner A et al.. Gender specific differences in left ventricular adaptation to obesity and hypertension.  J Hum Hypertens. 1998;  12 685-691
    CrossrefPubMedGoogle Scholar
  • 44 Dagenais G R, Maurice S, Robitaille N M, Gingras S, Lupien P J. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study.  Clin Invest Med. 1991;  14 93-100
    PubMedGoogle Scholar
  • 45 Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart study.  Br Heart J. 1994;  72 128-132
    CrossrefPubMedGoogle Scholar
  • 46 Smith G D, Shipley M J, Rose G. Intermittent claudication, heart disease risk factors and mortality: The Whitehall Study.  Circulation. 1990;  82 1925-1931
    PubMedGoogle Scholar
  • 47 Newman A B, Sutton-Tyrrell K, Vogt M T, Kuller L H. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index.  JAMA. 1993;  270 487-489
    CrossrefPubMedGoogle Scholar
  • 48 Planas A, Clara A, Pou J-M et al.. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men.  Int J Obes Relat Metab Disord. 2001;  25 1068-1070
    CrossrefPubMedGoogle Scholar
  • 49 Tsai A W, Chushman M, Rosamond W D et al.. Cardiovascular risk factors and venous thromboembolism incidence.  Arch Intern Med. 2002;  162 1182-1189
    CrossrefPubMedGoogle Scholar
  • 50 Hansson P-O, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity. Risk factors for venous thromboembolism among middle-aged men: “The Study of Men Born in 1913.”  Arch Intern Med. 1999;  159 1886-1890
    CrossrefPubMedGoogle Scholar
  • 51 Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;  89 493-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med. 2000;  160 3415-3420
    CrossrefPubMedGoogle Scholar
  • 53 White H R, Gettner S, Newman J, Trauner K B, Romano S P. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty.  N Engl J Med. 2000;  343 1758-1764
    CrossrefPubMedGoogle Scholar
  • 54 Padberg F, Cerveira J J, Lal B K, Pappas P J, Varma S, Hobson R W. Does severe venous insufficiency have a different etiology in the morbidly obese? It is venous?.  J Vasc Surg. 2003;  37 79-85
    CrossrefPubMedGoogle Scholar
  • 55 Vague P, Juhan-Vague I, Aillaud M F et al.. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.  Metabolism. 1986;  35 250-253
    CrossrefPubMedGoogle Scholar
  • 56 Quattrone A, Gambardella A, Carbone A M et al.. A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension.  J Neurol. 1999;  246 1086-1089
    PubMedGoogle Scholar
  • 57 Foster G D, Wadden T A, Phelan S, Sarwer D B. Obese patients’ perceptions of treatment outcomes and the factors that influence them.  Arch Intern Med. 2001;  161 2133-2139
    CrossrefPubMedGoogle Scholar
  • 58 Oster G, Thompson D, Edelsberg J, Bird A P, Colditz G A. Lifetime effect and economic benefits of weight loss among obese persons.  Am J Public Health. 1999;  89 1536-1542
    PubMedGoogle Scholar
  • 59 Blackburn G. Effect of degree of weight loss on health benefits.  Obes Res. 1995;  (suppl 2) 211S-216S
    PubMedGoogle Scholar
  • 60 Goldstein D J. Beneficial effects of modest weight loss.  Int J Obes Relat Metab Disord. 1992;  16 397-415
    PubMedGoogle Scholar
  • 61 Balsiger B M, Murr M M, Poggio J L, Sarr M G. Bariatric surgery. Surgery for weight control in patients with morbid obesity.  Med Clin North Am. 2000;  84 477-489
    CrossrefPubMedGoogle Scholar
  • 62 Guerciolini R. Mode of action of orlistat.  Int J Obes Relat Metab Disord. 1997;  21 (suppl) 3 S12-S52
    PubMedGoogle Scholar
  • 63 Finer N. Sibutramine: its mode of action and efficacy.  Int J Obes Relat Metab Disord. 2002;  26(suppl 4) S29-S33
    CrossrefPubMedGoogle Scholar
  • 64 Douketis J D, Feightner J W, Attia J, Feldman W F. Periodic health examination, 1999 update: detection, prevention, and treatment of obesity. Canadian Task Force on Preventive Health Care.  CMAJ. 1999;  160 513-524
    PubMedGoogle Scholar
  • 65 Douketis J D, Thabane L, Macie C, Williamson D F. The long-term effectiveness of weight reduction in obese and overweight adults: systematic review and generalizability of findings to clinical practice.  Int J Obes Relat Metabol Disord. 2005;  , In press
    PubMedGoogle Scholar
  • 66 Tuomilehto J, Lindström J, Eriksson J G et al.. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    CrossrefPubMedGoogle Scholar
  • 67 Eriksson K F, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise.  Diabetologia. 1991;  34 891-898
    CrossrefPubMedGoogle Scholar
  • 68 The Trials of Hypertension Prevention Collaborative Research Group . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II.  Arch Intern Med. 1997;  157 657-667
    CrossrefPubMedGoogle Scholar
  • 69 Stevens V J, Obarzanek E, Cook N R et al.. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, Phase II.  Ann Intern Med. 2001;  134 1-11
    CrossrefPubMedGoogle Scholar
  • 70 Whelton P K, Appel L J, Espeland M A et al.. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group.  JAMA. 1998;  279 839-846
    CrossrefPubMedGoogle Scholar
  • 71 Stamler R, Stamler J, Grimm R et al.. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial-The Hypertension Control Program.  JAMA. 1987;  257 1484-1491
    CrossrefPubMedGoogle Scholar
  • 72 Metz J A, Stern J S, Kris-Etherton P et al.. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction.  Arch Intern Med. 2000;  160 2150-2158
    CrossrefPubMedGoogle Scholar
  • 73 Pischon T, Douketis J D, Sharma A M. Evidence based medicine: weight loss and cardiovascular risk factor. In: Hofbaver KG, Keller U, Boss O Pharmacotherapy of Obesity Boca Raton, FL; CRC Press 2004: 155-172
    Google Scholar
  • 74 Hollander P A, Elbein S C, Hirsch I B et al.. Role of orlistat in the treatment of obese patients with type 2 diabetes.  Diabetes Care. 1998;  21 1288-1294
    CrossrefPubMedGoogle Scholar
  • 75 Lindgärde F. on behalf of the Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study.  J Intern Med. 2000;  248 245-254
    CrossrefPubMedGoogle Scholar
  • 76 Kelley D E, Bray G A, Pi-Sunyer F X et al.. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes.  Diabetes Care. 2002;  25 1033-1041
    CrossrefPubMedGoogle Scholar
  • 77 Miles J M, Leiter L, Hollander P et al.. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.  Diabetes Care. 2002;  25 1123-1128
    PubMedGoogle Scholar
  • 78 Sharma A M, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension.  J Hypertens. 2002;  20 1873-1878
    Google Scholar
  • 79 McMahon F G, Fujioka K, Singh B N et al.. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. A 1-year, double-blind, placebo-controlled, multicenter trial.  Arch Intern Med. 2000;  160 2185-2191
    CrossrefPubMedGoogle Scholar
  • 80 McMahon F G, Weinstein S P, Rowe E, Ernst K R, Johnson F, Fujioka K. and the Sibutramine in Hypertension Clinical Study Group . Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.  J Hum Hypertens. 2002;  16 5-11
    CrossrefPubMedGoogle Scholar
  • 81 Expert Panel on the Identification . Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.  Arch Intern Med. 1998;  158 1855-1867
    CrossrefPubMedGoogle Scholar
  • 82 Ornish D, Brown S E, Scherwitz L W et al.. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.  Lancet. 1990;  336 129-133
    CrossrefPubMedGoogle Scholar
  • 83 Haskell W L, Alderman E L, Fair J M et al.. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease.  Circulation. 1994;  89 975-990
    PubMedGoogle Scholar
  • 84 Niebauer J, Hambrecht R, Velich T et al.. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention.  Circulation. 1997;  96 2534-2541
    CrossrefPubMedGoogle Scholar
  • 85 Schuler G, Hambrecht R, Schlierf G et al.. Regular physical exercise and low-fat diet.  Circulation. 1992;  86 1-11
    PubMedGoogle Scholar
  • 86 Blood Pressure Lowering Trialists’ Collaboration . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.  Lancet. 2000;  355 1955-1964
    CrossrefPubMedGoogle Scholar
  • 87 Anonymous . Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of cardiovascular complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 88 Torgerson J S, Sjostrom L. The Swedish Obese Subjects (SOS) study - rationale and results.  Int J Obes Relat Metab Disord. 2001;  25 (suppl) 1 S2-S4
    CrossrefPubMedGoogle Scholar
  • 89 Ryan D H, Espeland M A, Foster G D et al.. Look AHEAD (Action for Health in Diabetes): design and method for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.  Control Clin Trials. 2003;  24(5) 610-628
    PubMedGoogle Scholar
  • 90 Decline in deaths from heart disease and stroke - United States, 1900-1999.  MMWR Morb Mortal Wkly Rep. 1999;  48 649-656
    PubMedGoogle Scholar

 Dr.
James D Douketis

St. Joseph’s Hospital

Room F-541, 50 Charlton Ave. East, Hamilton, ON

Canada, L8N 4A6

      >